Novel regulation of chondroitin sulfate glycosaminoglycan modification of amyloid precursor protein and its homologue, APLP2

J Biol Chem. 1995 Jul 14;270(28):16522-5. doi: 10.1074/jbc.270.28.16522.

Abstract

Alzheimer's disease is characterized by the presence of parenchymal and cerebrovascular deposits of beta-amyloid (A beta). A beta is derived from larger amyloid precursor proteins (APP), a member of a family of related polypeptides that includes amyloid precursor-like proteins, APLP1 and APLP2. APP and APLP2 isoforms are encoded by several alternatively spliced APP and APLP2 transcripts, respectively. We previously reported that the APLP2-751 isoform is modified by the addition of chondroitin sulfate glycosaminoglycan (CS GAG) at Ser-614. In this report, we demonstrate that the APLP2-763 isoform, which contains an insertion of 12 amino acids immediately N-terminal to Ser-614, is not modified by CS GAG. Finally, we demonstrate that like APLP2-751, APP isoforms that lack sequences encoded by exon 15 (L-APP) are also modified by CS GAG, whereas APP forms containing exon 15 are not. We suggest that CS GAG modification of a subset of APP and APLP2 isoforms represents a means of generating functional diversity for these polypeptides.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alternative Splicing
  • Amino Acid Sequence
  • Amyloid beta-Protein Precursor / genetics
  • Amyloid beta-Protein Precursor / metabolism*
  • Base Sequence
  • Cells, Cultured
  • Chondroitin Sulfates / pharmacology*
  • Humans
  • Molecular Sequence Data
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*

Substances

  • APLP1 protein, human
  • APLP2 protein, human
  • Amyloid beta-Protein Precursor
  • Nerve Tissue Proteins
  • chondroitin sulfate glycosaminoglycan
  • Chondroitin Sulfates